Literature DB >> 36002647

Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

Sharon Grisaru-Tal1, Marc E Rothenberg2, Ariel Munitz3.   

Abstract

Eosinophils are important effector cells and therapeutic targets in allergic diseases. Emerging data indicate that eosinophils infiltrate a variety of solid tumor types and have pleiotropic activities by at least two non-mutually exclusive mechanisms: direct interactions with tumor cells, and intricate cross-talk with lymphocytes. In light of the immune checkpoint inhibition revolution in cancer therapy, we review eosinophil-lymphocyte interactions in the tumor microenvironment. We also analyze potential interactions between eosinophils and lymphocyte subsets, including T cells, natural killer cells and innate lymphoid cells. We provide perspectives on the consequences of these interactions and how eosinophils are accessory cells that can affect the response to various forms of T cell-mediated immunotherapies and might be therapeutically targeted to improve cancer immunotherapy.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36002647      PMCID: PMC9554620          DOI: 10.1038/s41590-022-01291-2

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  72 in total

1.  Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Authors:  Ida Hude; Stephanie Sasse; Paul J Bröckelmann; Bastian von Tresckow; Jesko Momotow; Andreas Engert; Sven Borchmann
Journal:  Br J Haematol       Date:  2017-04-25       Impact factor: 6.998

Review 2.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

3.  Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity.

Authors:  Masashi Ikutani; Tsutomu Yanagibashi; Masaru Ogasawara; Koichi Tsuneyama; Seiji Yamamoto; Yuichi Hattori; Taku Kouro; Atsuko Itakura; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

4.  Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.

Authors:  B M Lang; A Peveling-Oberhag; D Faidt; A M Hötker; V Weyer-Elberich; S Grabbe; C Loquai
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

5.  Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration.

Authors:  J A Sosman; K Bartemes; K P Offord; H Kita; S G Fisher; C Kefer; T A Ellis; R I Fisher; T J Higgins; G J Gleich
Journal:  Clin Cancer Res       Date:  1995-08       Impact factor: 12.531

6.  Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer.

Authors:  Hadar Reichman; Michal Itan; Perri Rozenberg; Tal Yarmolovski; Eli Brazowski; Chen Varol; Nathan Gluck; Shiran Shapira; Nadir Arber; Udi Qimron; Danielle Karo-Atar; James J Lee; Ariel Munitz
Journal:  Cancer Immunol Res       Date:  2019-01-21       Impact factor: 11.151

7.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

Review 8.  Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.

Authors:  Rong En Tay; Emma K Richardson; Han Chong Toh
Journal:  Cancer Gene Ther       Date:  2020-05-27       Impact factor: 5.987

Review 9.  Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.

Authors:  David Y Oh; Lawrence Fong
Journal:  Immunity       Date:  2021-12-14       Impact factor: 43.474

10.  Innate immune cells in the tumor microenvironment.

Authors:  Ming O Li; Natalie Wolf; David H Raulet; Leila Akkari; Mikael J Pittet; Paulo C Rodriguez; Rosandra N Kaplan; Ariel Munitz; Zemin Zhang; Sijin Cheng; Nina Bhardwaj
Journal:  Cancer Cell       Date:  2021-06-14       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.